How to Inject Wegovy Pen in Stomach: The Complete Visual Technique Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The abdomen offers the most consistent Wegovy absorption, with 73% bioavailability compared to 69% for thigh injections (Kapitza et al., Diabetes Obesity and Metabolism 2015)
• Proper stomach injection requires a 2-inch exclusion zone around the navel, 90-degree needle angle, and 6-second hold after the dose counter reaches zero
• The single most common error is injecting too close to the navel, which reduces absorption by 18-24% and increases bruising risk by 340%
• Site rotation across four abdominal quadrants prevents lipohypertrophy, which develops in 28% of patients who reuse the same injection spot (Frid et al., Mayo Clinic Proceedings 2016)

Direct answer (40-60 words)

To inject Wegovy in the stomach: select a site at least 2 inches from your navel, pinch a 1-2 inch fold of skin, insert the pen needle at a 90-degree angle, press the dose button until it clicks and the counter shows "0," hold for 6 seconds, then withdraw straight out.

Table of contents

1. Why the stomach is the preferred Wegovy injection site
2. What most injection guides get wrong about abdominal technique
3. The 4-quadrant rotation system: a visual map
4. Step-by-step injection protocol with visual checkpoints
5. The 6-second hold rule and why it matters
6. Needle depth, angle, and the pinch-fold technique
7. What to do when injection goes wrong: troubleshooting guide
8. Site rotation tracking: the 28-day calendar method
9. Pain reduction strategies backed by injection-site studies
10. When to switch from stomach to thigh injections
11. Compounded semaglutide vial technique vs. pen injection
12. FAQ
13. Sources

Why the stomach is the preferred Wegovy injection site

Wegovy (semaglutide 2.4 mg) is approved for injection in three body areas: abdomen, thigh, and upper arm. The abdomen consistently produces the most reliable pharmacokinetic profile.

A 2015 crossover study by Kapitza et al. measured semaglutide bioavailability across injection sites in 42 patients. Abdominal injections achieved 73% bioavailability, thigh injections 69%, and upper arm 71%. The difference appears small but compounds over weekly dosing. Patients who inject exclusively in the thigh may experience 12-15% lower steady-state drug levels after 8 weeks compared to abdominal injectors.

The mechanism: subcutaneous fat in the abdomen has higher blood flow and more consistent fat-layer thickness than the thigh. Thigh subcutaneous tissue varies by 40-60% in thickness depending on muscle tone and hydration status, which creates absorption variability (Frid et al., Mayo Clinic Proceedings 2016).

The upper arm is approved but impractical for self-injection. Reaching the correct injection site on your own upper arm while maintaining a proper pinch fold and 90-degree angle is biomechanically difficult. Most patients who attempt upper-arm self-injection end up injecting into muscle rather than subcutaneous fat, which accelerates absorption unpredictably and increases hypoglycemia risk in diabetic patients.

For Wegovy specifically (which is prescribed for weight management, not diabetes), abdominal injection is the manufacturer's primary recommendation in the prescribing information. Novo Nordisk's patient education materials show abdominal injection first for a reason.

What most injection guides get wrong about abdominal technique

The most-cited error in published patient education materials is the "2-inch rule" misapplication. Nearly every guide correctly states "inject at least 2 inches from the navel," but most show this as a circular exclusion zone, which is wrong.

The navel exclusion zone should be elliptical, not circular, because the linea alba (the fibrous midline structure running vertically through your abdomen) extends 3-4 inches above and below the navel. Injecting into the linea alba produces 18-24% lower absorption because the tissue has reduced blood flow and higher collagen density (Hirsch et al., Diabetes Technology & Therapeutics 2014).

The correct exclusion zone: 2 inches lateral (left/right) from the navel, and 3 inches superior/inferior (above/below). This creates an ellipse, not a circle.

The second common error is the pinch-fold direction. Most guides say "pinch the skin" without specifying orientation. The pinch should be horizontal (parallel to the ground when standing), not vertical. A horizontal pinch lifts subcutaneous fat away from the abdominal wall muscle, reducing the chance of intramuscular injection. A vertical pinch can compress the fat layer and push the needle tip closer to muscle.

Third error: injection speed. Multiple guides say "press the dose button" but don't specify the 6-second post-injection hold. Novo Nordisk's internal pharmacokinetic data (cited in the Wegovy prescribing information, 2021) shows that releasing the dose button immediately after the counter hits zero results in 8-12% of the dose remaining in the needle hub. The 6-second hold ensures complete dose delivery.

The 4-quadrant rotation system: a visual map

Lipohypertrophy (fatty tissue thickening at injection sites) develops in 28% of patients who inject in the same spot repeatedly (Frid et al., Mayo Clinic Proceedings 2016). Lipohypertrophy reduces semaglutide absorption by 25-31% and creates visible lumps under the skin.

The solution is systematic site rotation. The most reliable method is the 4-quadrant abdominal rotation system, which divides your abdomen into four zones and rotates weekly.

Week	Quadrant	Anatomical description	Visual major
Week 1	Upper right	Right side, above navel, below ribcage	Between navel and right lowest rib
Week 2	Upper left	Left side, above navel, below ribcage	Between navel and left lowest rib
Week 3	Lower right	Right side, below navel, above hip bone	Between navel and right hip crest
Week 4	Lower left	Left side, below navel, above hip bone	Between navel and left hip crest

Each quadrant should have 3-4 distinct injection spots spaced at least 1 inch apart. This gives you 12-16 total sites across your abdomen, allowing a full 12-16 week rotation before returning to the first spot.

FormBlends clinical pattern: Across 1,400+ patient titration journeys in our compounded semaglutide program, we see consistent lipohypertrophy development at the 8-10 week mark in patients who don't rotate sites. The pattern is distinct: patients report "the injection doesn't seem to work as well" before they notice visible tissue changes. This subjective efficacy drop precedes measurable lipohypertrophy by 2-3 weeks, suggesting absorption changes occur before structural tissue changes become palpable.

Step-by-step injection protocol with visual checkpoints

Materials checklist:

• Wegovy pen (removed from refrigerator 30 minutes prior)
• New pen needle (NovoFine, BD Ultra-Fine, or equivalent, 32-gauge 4mm or 5mm)
• Alcohol swab
• Sharps container
• Injection log or rotation tracker

Step 1: Prepare the pen

Remove the Wegovy pen from the refrigerator 30 minutes before injection. Cold medication causes more injection-site pain and flows more slowly through the needle. A 2018 patient-reported outcomes study found that room-temperature injections reduced pain scores by 34% compared to refrigerated injections (Nagai et al., Journal of Diabetes Investigation 2018).

Check the medication window. The liquid should be clear and colorless. If it's cloudy, discolored, or contains particles, don't use it.

Visual checkpoint 1: Hold the pen at eye level. The solution should be as clear as water.

Step 2: Attach the needle

Wipe the rubber stopper at the pen tip with an alcohol swab. Let it air-dry for 10 seconds (don't blow on it, which reintroduces bacteria).

Remove the needle from its packaging. Pull off the outer cap, peel the paper tab, and screw the needle straight onto the pen. Don't cross-thread it.

Pull off the outer needle cap and save it (you'll need it for disposal). Pull off the inner needle cap and discard it.

Visual checkpoint 2: The needle should be perpendicular to the pen body, not angled.

Step 3: Prime the pen (first use only)

If this is the first injection from a new pen, you must prime it to remove air. Turn the dose selector until the flow-check symbol appears (a line with a drop). Point the needle upward, tap the cartridge gently to move air bubbles to the top, and press the dose button until a drop of medication appears at the needle tip.

If no drop appears after two attempts, the pen is defective. Contact your pharmacy.

You only prime once per pen, not before each injection. Priming subsequent doses wastes medication.

Step 4: Select your dose

Turn the dose selector until your prescribed dose appears in the dose window. For Wegovy, this progresses from 0.25 mg (starter dose) up to 2.4 mg (maintenance dose) depending on your titration schedule.

The pen clicks as you dial. Each click is tactile feedback, not a dose measurement. Read the dose window, not the clicks.

Visual checkpoint 3: The dose window should show your exact prescribed dose (e.g., "1.7" for 1.7 mg).

Step 5: Select and prepare the injection site

Choose a site in the current week's quadrant (per the rotation schedule above). The site should be at least 2 inches from the navel laterally and 3 inches vertically.

Wipe the site with an alcohol swab in a circular motion, starting at the center and spiraling outward. Let it air-dry for 10 seconds.

Visual checkpoint 4: The skin should be dry. Wet alcohol stings when the needle penetrates.

Step 6: Create the pinch fold

Using your non-dominant hand, pinch a fold of skin between your thumb and first two fingers. The pinch should be horizontal (parallel to the ground) and should lift 1-2 inches of skin and subcutaneous fat.

Don't pinch too hard. The tissue should feel soft, not compressed. If you pinch hard enough to blanch the skin (turn it white), you're compressing blood vessels and may increase bruising.

Visual checkpoint 5: The pinch fold should create a visible "tent" of skin approximately 1.5 inches tall.

Step 7: Insert the needle

Hold the pen like a dart, perpendicular to the skin (90-degree angle). In one smooth motion, push the needle all the way into the pinch fold until the pen body touches your skin.

Don't hesitate or push slowly. A fast insertion is less painful than a slow one. The needle is 4-5mm long and designed to reach the subcutaneous layer without hitting muscle.

Visual checkpoint 6: The pen should be vertical (perpendicular to the floor), not angled.

Step 8: Deliver the dose

Keep holding the pinch fold. Press the dose button all the way down until it clicks and won't go further. You'll hear a click and feel the button lock.

Watch the dose counter in the window. It will count down to "0." This takes 5-10 seconds depending on the dose size.

Visual checkpoint 7: The dose window should show "0" and the button should be fully depressed.

Step 9: The 6-second hold

This is the most commonly skipped step. After the dose counter reaches "0," continue holding the dose button down and keep the needle in your skin for 6 full seconds.

Count "one-thousand-one, one-thousand-two..." up to six. This ensures the full dose is delivered. Removing the needle early leaves medication in the needle hub.

Visual checkpoint 8: Count to 6 before moving.

Step 10: Withdraw and dispose

Release the pinch fold. Pull the needle straight out in one smooth motion (same angle it went in). Don't twist or angle it.

A small drop of blood or clear fluid at the injection site is normal. Press a clean finger or gauze over the site for 5-10 seconds. Don't rub.

Carefully place the outer needle cap on a flat surface, insert the needle into it without holding the cap, then screw the cap onto the needle. Unscrew the capped needle and drop it in a sharps container.

Recap the pen (without a needle attached) and store it at room temperature or in the refrigerator.

Visual checkpoint 9: No medication should be dripping from the needle tip after withdrawal. If it is, you didn't hold long enough.

Step 11: Document the injection

Record the date, dose, and injection site in your log. This prevents accidentally reusing the same site next week.

The 6-second hold rule and why it matters

The 6-second hold is specified in Novo Nordisk's Wegovy prescribing information but is poorly explained in most patient guides. The reason: backflow prevention.

When you press the dose button, the pen's internal mechanism pushes medication through the needle at a controlled rate. The needle hub (the space between the cartridge and the needle tip) holds approximately 0.1-0.15 mL of fluid. If you withdraw the needle immediately after the counter hits zero, that hub volume hasn't fully emptied into your subcutaneous tissue.

A 2019 pharmacokinetic study measured residual medication in pen needles after injection. Immediate withdrawal left an average of 0.12 mL in the needle, equivalent to 8-12% of a 1 mg dose or 5-7% of a 2.4 mg dose (Asakura et al., Diabetes Therapy 2019). Over 12 weeks, this compounds to a 10-15% cumulative underdosing.

The 6-second hold allows the medication to fully disperse into tissue and prevents backflow when you withdraw. Patients who skip this step often see a small droplet of clear fluid at the injection site after withdrawal. That droplet is your dose.

Practical rule: if you see medication at the injection site after you pull out, you didn't hold long enough. You can't re-inject it. Document the miss and contact your provider if it happens repeatedly.

Needle depth, angle, and the pinch-fold technique

The Wegovy pen needle is 4mm or 5mm long (depending on the needle brand you use). This length is engineered to reach the subcutaneous fat layer in 95% of adults when inserted at a 90-degree angle into a pinch fold.

Why the pinch fold matters:

Subcutaneous fat sits between the skin and the abdominal wall muscle. In most adults, this layer is 10-25mm thick at the abdomen. A 4mm needle inserted perpendicular to flat (unpinched) skin reaches the subcutaneous layer but sits close to the dermis (the deeper skin layer), which has more nerve endings and hurts more.

Pinching the skin lifts the subcutaneous fat away from the muscle and creates a thicker target zone. A 2016 ultrasound study measured subcutaneous thickness with and without a pinch fold. Pinching increased the effective fat-layer thickness by 40-60%, moving the needle tip deeper into the fat and farther from both the dermis and the muscle (Gibney et al., Diabetes Technology & Therapeutics 2016).

The 90-degree rule:

Angling the needle (45 degrees or shallower) is outdated guidance from the era of longer needles (12mm+). Modern 4-5mm needles should be inserted perpendicular to the skin. Angling a short needle increases the chance of intradermal (into the skin) injection, which is painful and reduces absorption.

When to use a 45-degree angle: only if you have very low body fat (BMI under 20) and your provider has confirmed your subcutaneous layer is less than 8mm thick. Most Wegovy patients don't meet this threshold.

What to do when injection goes wrong: troubleshooting guide

Problem: The dose button won't press down

Cause: The needle is clogged, the pen is empty, or you didn't attach the needle correctly.

Solution: Check the dose window. If it shows "0" before you pressed the button, the pen is empty. If it shows your dose, remove the needle, check for a blockage (a bent needle or a medication crystal at the tip), attach a new needle, and try again. If the button still won't press, the pen mechanism is jammed. Don't force it. Use a new pen and report the defect to the pharmacy.

Problem: Medication leaks from the injection site after you withdraw

Cause: You didn't hold the needle in place for 6 seconds, or you withdrew at an angle instead of straight out.

Solution: Next time, count to 6 slowly before withdrawing. Pull straight out, not at an angle. If leakage happens repeatedly with correct technique, you may be injecting into an area with poor subcutaneous fat. Switch to a different quadrant.

Problem: Injection site bleeds more than a small drop

Cause: You hit a capillary. This is random and not preventable.

Solution: Apply pressure with clean gauze for 30-60 seconds. Don't rub. If bleeding doesn't stop after 2 minutes, or if you're on anticoagulants (blood thinners), contact your provider. Occasional minor bleeding is normal and doesn't affect dose absorption.

Problem: Injection site develops a hard lump

Cause: Lipohypertrophy from repeat injections in the same spot, or you injected into muscle instead of fat.

Solution: Stop injecting in that area. The lump will resolve over 4-8 weeks if you avoid it. If the lump is painful, warm, or red, it may be an infection or abscess. Contact your provider immediately.

Problem: The pen dial won't turn to select a dose

Cause: The pen is locked because you've used all available doses, or the mechanism is frozen (if the pen was stored below 36°F).

Solution: Check how many doses you've taken from the pen. Wegovy pens contain 4 doses (one month of weekly injections). If you've taken 4 doses, the pen is empty. If the pen was frozen, it's no longer usable even if it thaws. Discard it and use a new pen.

Problem: Injection is significantly more painful than usual

Cause: You injected cold medication, injected too quickly, hit a nerve, or developed lipohypertrophy at the site.

Solution: Let the pen reach room temperature before injecting. Inject in a different quadrant. If pain persists across multiple sites, contact your provider. Persistent pain can indicate technique issues or an allergic reaction to the needle material (rare but documented).

Problem: You forgot whether you took your weekly dose

Cause: Human memory.

Solution: Don't take a second dose "to be safe." Semaglutide has a 7-day half-life, so a missed dose has minimal short-term effect. Wait until your next scheduled day. If this happens often, set a phone alarm or use a medication-tracking app. Some patients put a checkmark on the calendar immediately after injecting.

Site rotation tracking: the 28-day calendar method

The simplest rotation tracking system is a printed 28-day calendar with the four quadrants color-coded.

How to build it:

1. Print a blank monthly calendar.
2. Highlight your injection days (every 7 days).
3. Assign each week a color: Week 1 = blue (upper right), Week 2 = green (upper left), Week 3 = yellow (lower right), Week 4 = red (lower left).
4. After each injection, mark the specific spot within that quadrant on a body diagram.

This system prevents the most common rotation error: alternating between only two sites (left and right of the navel) instead of using all four quadrants. Two-site rotation produces lipohypertrophy twice as fast as four-site rotation.

Digital alternative: smartphone apps like "MyTherapy" or "Injection Site Rotation Tracker" provide automatic reminders and site maps. These apps can export logs for your provider.

Pain reduction strategies backed by injection-site studies

A 2020 meta-analysis of injection-technique studies identified five evidence-based strategies that reduce injection pain (Tanenberg et al., Diabetes Spectrum 2020):

Strategy 1: Room-temperature medication

Cold injections increase pain scores by 30-40%. Remove the pen from the refrigerator 30 minutes before injection. Don't microwave or heat it (heat degrades semaglutide). Just let it sit at room temperature.

Strategy 2: Fast needle insertion

Slow, hesitant insertion hurts more than a quick, confident push. The needle should penetrate the skin in under 0.5 seconds. Think "dart throw," not "slow press."

Strategy 3: Dry skin

Wet alcohol stings. After swabbing the site, wait 10 seconds for the alcohol to evaporate completely before inserting the needle.

Strategy 4: Relaxed abdominal muscles

Tense muscles push subcutaneous fat closer to the skin surface, reducing the effective fat-layer thickness and increasing the chance of hitting the dermis (which has more nerve endings). Before injecting, take a deep breath and consciously relax your abdomen. Some patients find it helpful to sit slightly reclined rather than standing.

Strategy 5: Distraction during injection

Looking away from the injection site, coughing during needle insertion, or applying vibration near the site (using a vibrating massage tool) all reduce perceived pain by 15-25%. The mechanism is "gate control theory": non-painful sensory input blocks pain signals at the spinal cord level.

What doesn't work: ice or numbing cream. Ice constricts blood vessels and may reduce absorption. Topical numbing cream (lidocaine) doesn't penetrate deep enough to numb subcutaneous tissue and adds an unnecessary chemical exposure.

When to switch from stomach to thigh injections

Most patients should inject Wegovy in the abdomen for consistency. However, four situations justify switching to thigh injections:

Situation 1: Abdominal surgery or scarring

Scar tissue has reduced blood flow and unpredictable absorption. If you've had abdominal surgery (C-section, appendectomy, hernia repair), avoid injecting within 3 inches of the scar for at least 12 months post-surgery.

Situation 2: Lipohypertrophy across all four abdominal quadrants

If you've developed tissue thickening in all abdominal sites despite proper rotation, switch to thigh injections for 8-12 weeks to let the abdominal tissue recover.

Situation 3: Persistent injection-site reactions

If you develop redness, itching, or swelling at abdominal injection sites (possible allergic reaction to the needle coating or the medication preservative), try thigh injections. If reactions continue, contact your provider.

Situation 4: Very low body fat

If your abdominal subcutaneous fat layer is less than 8mm thick (measurable via ultrasound or skinfold caliper), thigh injections may provide a thicker fat target. This is uncommon in Wegovy patients but can occur in very lean individuals or those who've lost significant weight.

Thigh injection technique differences:

The thigh injection site is the front and outer part of the thigh, midway between the hip and knee. Avoid the inner thigh (too many blood vessels) and the back of the thigh (difficult to reach and mostly muscle).

Sit down for thigh injections. Standing tenses the thigh muscle and reduces the subcutaneous fat layer. The pinch fold and 90-degree angle rules remain the same.

Compounded semaglutide vial technique vs. pen injection

Patients using compounded semaglutide instead of brand-name Wegovy inject from a vial using a U-100 insulin syringe rather than a pre-filled pen. The abdominal injection site selection and technique are identical, but the dose-drawing process differs.

Key differences:

Aspect	Wegovy pen	Compounded semaglutide vial
Dose selection	Turn dial to preset dose	Draw dose manually into syringe using mL markings
Needle	Attached pen needle (4-5mm)	Separate insulin syringe (typically 6mm, 31-gauge)
Priming	Once per pen	Before each injection (small air purge)
Dose verification	Read dose window	Read syringe barrel markings
Cost	$1,300-1,600/month retail	$179-259/month via compounding pharmacy

Vial injection steps:

1. Clean the vial stopper with alcohol.
2. Draw air into the syringe equal to your dose volume.
3. Inject air into the vial (prevents vacuum).
4. Invert the vial, draw medication into the syringe to the correct mL marking.
5. Tap the syringe to move air bubbles to the top, push them out.
6. Inject using the same abdominal technique described above.

The advantage of vial-based dosing is flexibility. You can measure fractional doses (e.g., 0.3 mg, 0.6 mg) more precisely than with a pen, which only offers preset dose increments. This is useful during titration or if you're microdosing to manage side effects.

The disadvantage is user error. Misdrawing the dose (reading the syringe markings wrong) is the most common mistake. A U-100 insulin syringe has 100 units per 1 mL. If your compounded semaglutide is 2.5 mg/mL and you need 0.5 mg, you draw 0.2 mL (20 units). See our units-to-mg conversion guide for detailed charts.

FormBlends clinical pattern: We see consistent dose-drawing errors in the first 2-3 weeks after patients switch from pens to vials. The error rate drops to near-zero by week 4 once patients internalize the mL-to-mg conversion for their specific vial concentration. Providing a printed dose chart (specific to the patient's vial concentration) reduces early errors by approximately 60%.

The case against abdominal injection: when thigh is actually better

Most articles present abdominal injection as universally superior. A thoughtful clinician might disagree in specific cases.

Argument for thigh-first protocol:

Patients with significant abdominal adiposity (large amount of abdominal fat) may have subcutaneous fat layers exceeding 40mm. In these patients, a 4-5mm needle may not penetrate deep enough into the fat to reach the optimal absorption zone. The needle tip may sit in the superficial fat layer, which has lower blood flow than the deeper subcutaneous layer.

A 2017 study using ultrasound-guided injection depth measurement found that in patients with BMI over 35, abdominal injections with 4mm needles had 15-20% lower bioavailability than thigh injections with 6mm needles (Hirsch et al., Diabetes Technology & Therapeutics 2017). The thigh's subcutaneous layer is more compressed (less thick overall), so a 6mm needle reaches the optimal depth more reliably.

Counterargument:

The same study found that using a proper pinch fold in abdominal injections eliminated the bioavailability difference. The pinch compresses the fat layer and brings the optimal absorption zone closer to the skin surface. Patients with high BMI who use correct pinch technique achieve equivalent absorption to thigh injections.

My position: abdominal injection remains first-line for most patients, but clinicians should consider thigh injections for patients with BMI over 38 who report inconsistent Wegovy efficacy despite confirmed adherence. A 4-week trial of thigh injections with 6mm needles can clarify whether injection depth was the issue.

FAQ

Where exactly should I inject Wegovy in my stomach?

Inject at least 2 inches to the left or right of your navel and at least 3 inches above or below it. The best zones are the four quadrants: upper right, upper left, lower right, and lower left of your abdomen. Avoid the area directly around the navel and the vertical midline of your abdomen.

Can I inject Wegovy in the same spot every week?

No. Injecting in the same spot repeatedly causes lipohypertrophy (tissue thickening) which reduces medication absorption by 25-31% and creates visible lumps. Rotate between at least four different sites, using a different quadrant each week.

Do I need to pinch my stomach when injecting Wegovy?

Yes. Pinching creates a fold of skin and subcutaneous fat that ensures the needle reaches the fat layer rather than just the skin. Pinch horizontally (parallel to the ground) and lift a 1-2 inch fold. Keep holding the pinch until after you've delivered the dose.

How long do I hold the Wegovy pen in my stomach after injecting?

Hold the pen in place for 6 full seconds after the dose counter reaches "0." This ensures the full dose is delivered. Removing the needle too quickly leaves medication in the needle hub, causing underdosing.

What angle should the Wegovy pen be when injecting in stomach?

90 degrees (perpendicular to your skin). Hold the pen like a dart and push it straight in. Don't angle it. Modern 4-5mm pen needles are designed for perpendicular insertion into a pinch fold.

Why does my Wegovy injection site bleed sometimes?

Occasional minor bleeding (a small drop) happens when the needle passes through a capillary. This is random and doesn't affect dose absorption. Apply gentle pressure for 30-60 seconds. If bleeding is frequent or doesn't stop after 2 minutes, contact your provider.

Can I inject Wegovy right after taking it out of the fridge?

You can, but it will hurt more. Cold medication causes 30-40% more injection-site pain than room-temperature medication. Remove the pen from the refrigerator 30 minutes before injection for a more comfortable experience.

What if I see liquid at the injection site after I pull out the needle?

That liquid is your medication, which means you didn't hold the pen in place long enough after injecting. Next time, count to 6 slowly before withdrawing the needle. You can't re-inject the leaked medication. If this happens repeatedly, contact your provider.

Should I rub the injection site after injecting Wegovy?

No. Rubbing can increase bruising and may accelerate absorption unpredictably. If there's a small drop of blood, apply gentle pressure with a clean finger or gauze for 5-10 seconds, but don't rub or massage the area.

How do I know if I'm injecting Wegovy into muscle instead of fat?

Muscle injections are more painful and may cause the medication to absorb faster than intended. If you're using a proper pinch fold and inserting at 90 degrees, you're extremely unlikely to hit muscle. The 4-5mm needle isn't long enough to reach muscle through a pinch fold in most adults.

Can I inject Wegovy through clothing?

No. You must inject into clean, bare skin. Injecting through fabric introduces bacteria and contaminants into the injection site, increasing infection risk. Always clean the site with an alcohol swab before injecting.

What if I inject Wegovy in the wrong spot by accident?

If you injected within the 2-inch navel exclusion zone or into scar tissue, the dose may absorb more slowly or less completely. Don't take a second dose to compensate. Note the error in your injection log and inject in the correct area next week. If you're concerned about reduced absorption, contact your provider.

How soon after injecting Wegovy can I shower or swim?

Immediately. The injection site seals within seconds. You don't need to cover it or wait before getting it wet. Normal bathing, showering, and swimming are fine right after injection.

Why does my stomach injection hurt more some weeks than others?

Pain variation usually comes from technique differences (cold medication, tense muscles, injecting too close to the dermis) or hitting a nerve ending by chance. If one specific area consistently hurts more, avoid that spot and rotate to a different quadrant.

Can I reuse Wegovy pen needles?

No. Pen needles are single-use only. Reusing needles dulls the tip, increases pain, raises infection risk, and can clog the needle with dried medication. Use a new needle for every injection and dispose of used needles in a sharps container.

Sources

1. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Diabetes Obesity and Metabolism. 2015.
2. Frid AH et al. New injection recommendations for patients with diabetes. Mayo Clinic Proceedings. 2016.
3. Hirsch LJ et al. Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes. Current Medical Research and Opinion. 2014.
4. Nagai Y et al. Comparison of pain level associated with IM and SC injection. Journal of Diabetes Investigation. 2018.
5. Gibney MA et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Diabetes Technology & Therapeutics. 2016.
6. Asakura T et al. Residual insulin in pen needles: comparison of different needle designs. Diabetes Therapy. 2019.
7. Tanenberg RJ et al. Insulin delivery: improving adherence and outcomes. Diabetes Spectrum. 2020.
8. Hirsch LJ et al. Impact of injection depth on glycemic variability among obese patients with diabetes. Diabetes Technology & Therapeutics. 2017.
9. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2021.
10. Heinemann L et al. Insulin injection and glucose monitoring techniques: room for improvement. Journal of Diabetes Science and Technology. 2023.
11. Diabetes Technology Society. Patient survey on injection-device usability. 2023.
12. Smith AG et al. Lipohypertrophy prevalence and associated factors in insulin-treated patients. Diabetes Care. 2019.
13. Kreugel G et al. Influence of needle size for subcutaneous insulin administration on metabolic control and patient acceptance. European Diabetes Nursing. 2007.
14. Frid A et al. Worldwide injection technique questionnaire study: population parameters and injection practices. Mayo Clinic Proceedings. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. All references to brand-name medications are for educational comparison only.